A prospective, randomized, double-blinded, vehicle- and placebo-controlled, multicenter clinical study of Injectable-discogenic-cell-therapy (IDCT) in subjects with single-level, symptomatic lumbar intervertebral disc degeneration

Trial Profile

A prospective, randomized, double-blinded, vehicle- and placebo-controlled, multicenter clinical study of Injectable-discogenic-cell-therapy (IDCT) in subjects with single-level, symptomatic lumbar intervertebral disc degeneration

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Injectable-discogenic-cell-therapy-DiscGenics (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Oct 2017 Patient gender is assumed.
    • 09 Oct 2017 New trial record
    • 03 Oct 2017 According to a DiscGenics media release, Investigational New Drug (IND) Application has been approved.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top